NICE Approves Dual Immunotherapy for Aggressive Bowel Cancer

Dual immunotherapy for bowel cancer now available under NHS - Pharmafile

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), and recommended by the National Institute for Health and Care Excellence (NICE). It is now a treatment option via NHS-funded commissioning, marking a major milestone for treating patients with […] The post Dual immunotherapy for bowel cancer now available under NH…

NICE Approves Dual Immunotherapy for Aggressive Bowel Cancer

NICE has approved nivolumab plus ipilimumab for NHS use in patients with aggressive colorectal cancer, following new evidence of clinical benefit.